Congratulations to Richard Leiter, MD Dana-Farber who is a 2024 Hastings Center Cunniff-Dixon Physician Award recipient. Leiter received the Early-Career Physician Award for his work in palliative care. Read more here: ms.spr.ly/6019lUw03

In a new study published in @scienceadvances, Ellis Reinherz, MD, Aoi Akitsu, and @danafarber researchers unveil the power of physical forces in enhancing T cell immune response. Research Summary ▶️ ms.spr.ly/6019lqbHz

Thanks WEEI & The Jimmy Fund for hosting me & my incredible patient, Ryan, who’s inspired my team & me Dana-Farber w/ his grit & fun-loving spirit as he faces a rare sarcoma #dsrct. He shared his story live to make things better for others #RFLSTRONG #KCANCER Dana-Farber News

Thousands of cyclists recently biked more than a million miles for the annual Pan-Mass Challenge Challenge, which has helped fund more than half of all cancer drugs approved by the FDA in the last five years. It is celebrating $1 billion raised since it started: “The winner is all of us.”

Harold Burstein, MD, PhD, (Harold J. Burstein, MD, PhD, FASCO) joined AJMC to discuss the crucial role of strong patient-physician partnerships in breast cancer treatment. Read more ➡️ ms.spr.ly/6013lS951

Eliezer “Eli” Van Allen, MD (Eli Van Allen) has been named the inaugural incumbent of the Chandra Nohria Family Chair for AI in Cancer Research Dana-Farber.

The inactive X chromosome in females can influence cancer risk and development. New research in Cell looks at how this drives sex bias in tRCC, an aggressive subtype of kidney cancer more common in females. ms.spr.ly/6017lt6Yc Dana-Farber Lank Center for Genitourinary Oncology Srinivas Viswanathan

Our study on sex differences in Xp11 translocation renal cell carcinoma is out Cell! We ascribe a genetic basis to the female bias in tRCC, which is driven by a translocation of the TFE3 gene on the X chromosome. w Zhang lab @danafarbernews bit.ly/4dtpNtP 🧵1/

Dana-Farber's Andrew Aguirre, MD, PhD, featured in National Cancer Institute discussing research in circulating tumor DNA in blood samples taken from people with pancreatic cancer before and after treatment with a KRAS-targeted drug. Read more: ms.spr.ly/6012lxLX6 CC: Hale Family Center For Pancreatic Cancer Research

Phase III clinical trial results published in NEJM. LITESPARK-005 supports FDA approval of belzutifan for patients with advanced #kidneycancer. Research led by Toni Choueiri, MD #RCC Read more: ms.spr.ly/6011lxfKL cc: Dana-Farber Lank Center for Genitourinary Oncology Dana-Farber

It is an honor to be listed among these exceptional leaders of academic medical centers by Becker's Hospital Review who are devoted to delivering excellent patient care while advancing innovative research. beckershospitalreview.com/lists/96-acade…

Shirley and Mike Joseph share their story of Shirley's #InflammatoryBreastCancer diagnosis and treatment Dana-Farber's specialized Inflammatory Breast Cancer Program. #IBC Dana-Farber IBC Program Letícia Varella 👉Full story here: blog.dana-farber.org/insight/2024/0…

Research in NEJM published by Dana-Farber's Toni Choueiri, MD supports belzutifan as a new treatment option in patients with advanced #kidneycancer. Read more from a woman who saw her tumors shrink after starting the treatment. ➡️ ms.spr.ly/6015l4MeW

A discover by Dana-Farber researchers in the Polyak Lab opens the door to potential new treatments targeting #KDM6A protein to prevent #BrainMetastasis in patients with #TrippleNegativeBreastCancer. Learn more here⬇️ blog.dana-farber.org/insight/2024/0…

Congratulations to our vice president for inpatient and ancillary services, Neha Gaur for being selected as one of @bosbizjournal's 40 under 40 honorees! #BBJ4040

Laurie H. Glimcher, MD, Dana-Farber’s transformative President and CEO, announced today that she will step down on October 1, 2024, and will assume the title of President Emerita. Benjamin Levine Ebert, MD, PhD, chair of Department of Medical Oncology and a world-renowned

"Glimcher has always been a trailblazer, whether in the lab uncovering scientific breakthroughs or the corner office as the first woman to head Dana-Farber in its 77-year history." Read more from Shirley Leung of The Boston Globe: bostonglobe.com/2024/09/04/bus…

New research from Dana-Farber’s Dipanjan Chowdury and Alexander Spektor reveals that cancers may be more dependent on CDK5 for their cell division than previously understood, presenting a possible new therapeutic target in cancer. dana-farber.org/newsroom/news-…

Featured in TIME, Dana-Farber's Toni Choueiri, MD, discusses research in targeted therapies and vaccines in #kidneycancer. Toni Choueiri, MD Dana-Farber Lank Center for Genitourinary Oncology Dana-Farber Read more here: ms.spr.ly/6019m13tU